Comparative Pharmacology
Head-to-head clinical analysis: LIDOCAINE HYDROCHLORIDE 0 4 AND DEXTROSE 5 IN PLASTIC CONTAINER versus SCANDONEST L.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIDOCAINE HYDROCHLORIDE 0 4 AND DEXTROSE 5 IN PLASTIC CONTAINER versus SCANDONEST L.
LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER vs SCANDONEST L
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine is a amide-type local anesthetic that blocks voltage-gated sodium channels in neuronal membranes, inhibiting the initiation and conduction of nerve impulses. Dextrose provides calories and does not have pharmacological activity.
Scandonest L (mepivacaine hydrochloride) is an amide-type local anesthetic that stabilizes neuronal membranes by inhibiting sodium ion influx across the membrane, thereby blocking nerve impulse initiation and conduction.
Intravenous administration: 1-1.5 mg/kg bolus, followed by 1-4 mg/min continuous infusion for ventricular arrhythmias. Maximum total dose: 3 mg/kg bolus; infusion for up to 24 hours. Note: 0.4% concentration = 4 mg/mL, 5% dextrose as diluent.
Dental infiltration or nerve block: 1.3 mL of 3% solution (isocaine) per site; maximum 9 mg/kg (0.3 mL/kg) per session. Infiltration: 0.5-1.0 mL; nerve block: 1.0-1.3 mL.
None Documented
None Documented
Terminal elimination half-life: 1.5–2 hours after a single dose in healthy adults. In patients with hepatic impairment, heart failure, or prolonged infusion, half-life can increase to >3 hours due to reduced clearance. Neonates: 3–6.3 hours.
Terminal elimination half-life is 1.5–2.0 hours in healthy adults; prolonged to 3–5 hours in patients with hepatic impairment or severe renal disease.
Renal: Approximately 90% of lidocaine is metabolized in the liver, and less than 10% is excreted unchanged in urine. The major metabolites (monoethylglycinexylidide and glycinexylidide) are excreted renally. Biliary/fecal excretion is minimal (<1%).
Primarily hepatic metabolism (approx. 90%) via amidase hydrolysis and aromatic hydroxylation; renal excretion of unchanged drug accounts for <5% of the dose; less than 1% excreted in feces.
Category A/B
Category C
Local Anesthetic / Antiarrhythmic (Class Ib)
Local Anesthetic